Onasemnogene abeparvovec (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Onasemnogene abeparvovec" in English language version.

refsWebsite

Global rank English rank

40web.archive.org

1^st place

5novartis.com

low place

4fda.gov

447^th place

338^th place

4europa.eu

68^th place

117^th place

4nih.gov

4^th place

3reuters.com

49^th place

47^th place

3tga.gov.au

3,984^th place

2,622^nd place

2newswire.ca

2,726^th place

1,608^th place

2theguardian.com

12^th place

11^th place

2hres.ca

low place

1medicines.org.uk

3,823^rd place

2,387^th place

1ten-navi.com

low place

1mhlw.go.jp

1,656^th place

low place

1novartis.co.jp

low place

1cadth.ca

low place

1raps.org

low place

1thepeninsulaqatar.com

5,487^th place

3,884^th place

1jewishpress.com

low place

6,955^th place

1globo.com

62^nd place

304^th place

1vedomosti.ru

721^st place

4,373^rd place

1straitstimes.com

543^rd place

346^th place

1worldcat.org

5^th place

1lexology.com

low place

6,257^th place

1yahoo.com

38^th place

40^th place

1fiercepharma.com

low place

8,921^st place

1prescrire.org

low place

1beneluxa.org

low place

1sma-europe.eu

low place

1wsj.com

79^th place

65^th place

1handle.net

102^nd place

76^th place

beneluxa.org

"No "lottery for life" - Statement by Beneluxa Health Ministers addressing the global managed access program designed by Novartis and Avexis". Beneluxa. 30 January 2020. Archived from the original on 22 May 2020. Retrieved 21 April 2020.

cadth.ca

"onasemnogene abeparvovec". Canadian Agency for Drugs and Technologies in Health (CADTH). 26 May 2020. Archived from the original on 2 June 2021. Retrieved 1 June 2021.

europa.eu

ema.europa.eu

"Zolgensma EPAR". European Medicines Agency (EMA). 24 March 2020. Archived from the original on 17 July 2020. Retrieved 30 July 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"EU/3/15/1509". European Medicines Agency. 17 September 2018. Archived from the original on 19 November 2019. Retrieved 19 November 2019.

ec.europa.eu

"Zolgensma Product information". Union Register of medicinal products. Retrieved 3 March 2023.

europarl.europa.eu

Kyriakides S (19 February 2020). "Answer given by Ms Kyriakides on behalf of the European Commission". European Parliament. Archived from the original on 28 October 2020. Retrieved 21 April 2020.

fda.gov

"Zolgensma". U.S. Food and Drug Administration (FDA). 6 August 2019. STN: 125694. Archived from the original on 19 November 2019. Retrieved 1 November 2019. This article incorporates text from this source, which is in the public domain.
"FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality". U.S. Food and Drug Administration (FDA). 24 May 2019. Archived from the original on 1 September 2019. Retrieved 18 November 2019. This article incorporates text from this source, which is in the public domain.
"Statement on data accuracy issues with recently approved gene therapy". U.S. Food and Drug Administration (FDA) (Press release). 19 November 2019. Archived from the original on 19 November 2019. Retrieved 1 December 2019. This article incorporates text from this source, which is in the public domain.

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

fiercepharma.com

Palmer, Eric (24 September 2019). "Novartis to put AveXis into protective custody after data manipulation scandal". Fierce Biotech. Retrieved 12 May 2024.

globo.com

g1.globo.com

"Medicamento conhecido como mais caro do mundo recebe registro da Anvisa". G1 (in Brazilian Portuguese). 17 August 2020. Archived from the original on 31 August 2020. Retrieved 18 August 2020.

handle.net

hdl.handle.net

World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 79". WHO Drug Information. 32 (1): 95–6. hdl:10665/330941.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Zolgensma". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.

pdf.hres.ca

"PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION : ZOLGENSMA" (PDF). Pdf.hres.ca. Archived (PDF) from the original on 14 June 2021. Retrieved 24 March 2022.

jewishpress.com

Julian HL (21 November 2019). "In First, World's Most Expensive Medicine Used to Treat Israeli Toddler". Archived from the original on 29 March 2020. Retrieved 29 March 2020.

lexology.com

Mueller, Casimir Jones SC-Lisa L. (September 2020). "First Gene Therapy Products Approved in Brazil". Lexology. Archived from the original on 2 June 2021. Retrieved 1 June 2021.

medicines.org.uk

"Zolgensma 2 x 1013 vector genomes/mL solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 30 June 2020. Archived from the original on 28 October 2020. Retrieved 30 July 2020.

mhlw.go.jp

厚生労働省告示第二百十四号 Archived 31 October 2020 at the Wayback Machine (Japanese). Ministry of Health, Labour and Welfare, Japan.

newswire.ca

"Health Canada approves Zolgensma, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)" (Press release). Novartis. 16 December 2020. Archived from the original on 3 June 2021. Retrieved 2 July 2021 – via Cision.
"Health Canada approves Zolgensma, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)" (Press release). Novartis Pharmaceuticals Canada. 16 December 2020. Archived from the original on 3 June 2021. Retrieved 27 May 2021 – via Cision.

nih.gov

dailymed.nlm.nih.gov

"Zolgensma- onasemnogene abeparvovec-xioi kit full prescribing information". DailyMed. 24 May 2019. Archived from the original on 19 November 2019. Retrieved 18 November 2019.

ncbi.nlm.nih.gov

"Onasemnogene Abeparvovec". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf. 20 August 2020. PMID 33242238. Bookshelf ID: NBK564658. Archived from the original on 14 August 2022. Retrieved 13 August 2022.

pubmed.ncbi.nlm.nih.gov

"Onasemnogene Abeparvovec". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf. 20 August 2020. PMID 33242238. Bookshelf ID: NBK564658. Archived from the original on 14 August 2022. Retrieved 13 August 2022.

pubchem.ncbi.nlm.nih.gov

"Onasemnogene abeparvovec (USAN/INN)". PubChem. Archived from the original on 9 September 2021. Retrieved 9 September 2021.

novartis.co.jp

脊髄性筋萎縮症に対する遺伝子治療用製品「ゾルゲンスマ®点滴静注」薬価基準収載のお知らせ Archived 28 October 2020 at the Wayback Machine (Japanese). Novartis Pharma.

novartis.com

"Novartis successfully completes acquisition of AveXis, Inc" (Press release). Novartis. Archived from the original on 9 September 2019. Retrieved 6 October 2018.
"AveXis receives FDA approval for Zolgensma, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)". Novartis (Press release). 24 May 2019. Retrieved 13 August 2022.
"Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma the only gene therapy for patients with spinal muscular atrophy (SMA)". Novartis (Press release). Retrieved 29 March 2020.
"Global Novartis News Archive". Novartis (Press release). Archived from the original on 29 May 2020. Retrieved 20 May 2020.
"New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment". Novartis. Archived from the original on 2 June 2021. Retrieved 1 June 2021.

prescrire.org

english.prescrire.org

"Zolgensma°: the drug of extremes". April 2020. p. 107. Archived from the original on 29 October 2020. Retrieved 22 May 2020.

raps.org

"Novartis' Zolgensma Joins Growing List of Medicines to Lose Accelerated Assessment Status in EU". RAPS. Archived from the original on 19 November 2019. Retrieved 19 November 2019.

reuters.com

Miller, John (30 October 2019). "Novartis' Zolgensma study halted by FDA amid safety questions". Reuters. Archived from the original on 30 October 2019. Retrieved 30 October 2019.
"Novartis says delayed telling FDA of Zolgensma concern due to 'mistake'". Reuters. 1 November 2019. Archived from the original on 11 November 2019. Retrieved 11 November 2019.
"Novartis in talks with patients upset about lottery-like gene therapy giveaway". Reuters. 20 December 2019. Archived from the original on 1 June 2021. Retrieved 29 May 2021.

sma-europe.eu

"AVXS-101 (Zolgensma) to be made available globally through a controversial programme". SMA Europe. 26 December 2019. Archived from the original on 13 March 2020. Retrieved 21 April 2020.

straitstimes.com

Iau, Jean (19 May 2023). "Toddler with rare genetic condition can be treated after $2m raised, drug registered". The Straits Times. ISSN 0585-3923. Retrieved 20 May 2023.

ten-navi.com

answers.ten-navi.com

初の「億超え新薬」ゾルゲンスマの薬価はどう決まったか Archived 15 August 2020 at the Wayback Machine (Japanese). AnswersNews.

tga.gov.au

"Zolgensma". Therapeutic Goods Administration (TGA). 10 March 2021. Archived from the original on 9 September 2021. Retrieved 8 September 2021.
"AusPAR: Onasemnogene abeparvovec". Therapeutic Goods Administration (TGA). 22 April 2021. Archived from the original on 9 September 2021. Retrieved 8 September 2021.

ebs.tga.gov.au

"TGA eBS - Product and Consumer Medicine Information Licence". Ebs.tga.gov.au. Archived from the original on 9 September 2021. Retrieved 24 March 2022.

theguardian.com

"$2.1m Novartis gene therapy to become world's most expensive drug". The Guardian. London. Reuters. 25 May 2019. Archived from the original on 7 November 2020. Retrieved 25 May 2019.
"Dismay at lottery for $2.1m drug to treat children with muscle-wasting disease". The Guardian. 20 December 2019. Archived from the original on 21 December 2019. Retrieved 21 December 2019.

thepeninsulaqatar.com

"HMC implements innovative gene therapy to treat congenital spinal muscular atrophy". The Peninsula. 20 November 2019. Archived from the original on 29 March 2020. Retrieved 29 March 2020.

vedomosti.ru

"Минздрав зарегистрировал препарат для лечения СМА «Золгенсма»". Ведомости (in Russian). 9 December 2021. Archived from the original on 10 December 2021. Retrieved 8 July 2022.

web.archive.org

"Zolgensma". Therapeutic Goods Administration (TGA). 10 March 2021. Archived from the original on 9 September 2021. Retrieved 8 September 2021.
"AusPAR: Onasemnogene abeparvovec". Therapeutic Goods Administration (TGA). 22 April 2021. Archived from the original on 9 September 2021. Retrieved 8 September 2021.
"Summary Basis of Decision (SBD) for Zolgensma". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
"Zolgensma 2 x 1013 vector genomes/mL solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 30 June 2020. Archived from the original on 28 October 2020. Retrieved 30 July 2020.
"Zolgensma- onasemnogene abeparvovec-xioi kit full prescribing information". DailyMed. 24 May 2019. Archived from the original on 19 November 2019. Retrieved 18 November 2019.
"Zolgensma". U.S. Food and Drug Administration (FDA). 6 August 2019. STN: 125694. Archived from the original on 19 November 2019. Retrieved 1 November 2019. This article incorporates text from this source, which is in the public domain.
"Zolgensma EPAR". European Medicines Agency (EMA). 24 March 2020. Archived from the original on 17 July 2020. Retrieved 30 July 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
初の「億超え新薬」ゾルゲンスマの薬価はどう決まったか Archived 15 August 2020 at the Wayback Machine (Japanese). AnswersNews.
厚生労働省告示第二百十四号 Archived 31 October 2020 at the Wayback Machine (Japanese). Ministry of Health, Labour and Welfare, Japan.
脊髄性筋萎縮症に対する遺伝子治療用製品「ゾルゲンスマ®点滴静注」薬価基準収載のお知らせ Archived 28 October 2020 at the Wayback Machine (Japanese). Novartis Pharma.
"Onasemnogene Abeparvovec". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf. 20 August 2020. PMID 33242238. Bookshelf ID: NBK564658. Archived from the original on 14 August 2022. Retrieved 13 August 2022.
"FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality". U.S. Food and Drug Administration (FDA). 24 May 2019. Archived from the original on 1 September 2019. Retrieved 18 November 2019. This article incorporates text from this source, which is in the public domain.
"Health Canada approves Zolgensma, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)" (Press release). Novartis. 16 December 2020. Archived from the original on 3 June 2021. Retrieved 2 July 2021 – via Cision.
"onasemnogene abeparvovec". Canadian Agency for Drugs and Technologies in Health (CADTH). 26 May 2020. Archived from the original on 2 June 2021. Retrieved 1 June 2021.
"Novartis successfully completes acquisition of AveXis, Inc" (Press release). Novartis. Archived from the original on 9 September 2019. Retrieved 6 October 2018.
"EU/3/15/1509". European Medicines Agency. 17 September 2018. Archived from the original on 19 November 2019. Retrieved 19 November 2019.
"Novartis' Zolgensma Joins Growing List of Medicines to Lose Accelerated Assessment Status in EU". RAPS. Archived from the original on 19 November 2019. Retrieved 19 November 2019.
"HMC implements innovative gene therapy to treat congenital spinal muscular atrophy". The Peninsula. 20 November 2019. Archived from the original on 29 March 2020. Retrieved 29 March 2020.
Julian HL (21 November 2019). "In First, World's Most Expensive Medicine Used to Treat Israeli Toddler". Archived from the original on 29 March 2020. Retrieved 29 March 2020.
"Global Novartis News Archive". Novartis (Press release). Archived from the original on 29 May 2020. Retrieved 20 May 2020.
"Medicamento conhecido como mais caro do mundo recebe registro da Anvisa". G1 (in Brazilian Portuguese). 17 August 2020. Archived from the original on 31 August 2020. Retrieved 18 August 2020.
"Health Canada approves Zolgensma, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)" (Press release). Novartis Pharmaceuticals Canada. 16 December 2020. Archived from the original on 3 June 2021. Retrieved 27 May 2021 – via Cision.
"PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION : ZOLGENSMA" (PDF). Pdf.hres.ca. Archived (PDF) from the original on 14 June 2021. Retrieved 24 March 2022.
"TGA eBS - Product and Consumer Medicine Information Licence". Ebs.tga.gov.au. Archived from the original on 9 September 2021. Retrieved 24 March 2022.
"Минздрав зарегистрировал препарат для лечения СМА «Золгенсма»". Ведомости (in Russian). 9 December 2021. Archived from the original on 10 December 2021. Retrieved 8 July 2022.
Mueller, Casimir Jones SC-Lisa L. (September 2020). "First Gene Therapy Products Approved in Brazil". Lexology. Archived from the original on 2 June 2021. Retrieved 1 June 2021.
"New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment". Novartis. Archived from the original on 2 June 2021. Retrieved 1 June 2021.
"$2.1m Novartis gene therapy to become world's most expensive drug". The Guardian. London. Reuters. 25 May 2019. Archived from the original on 7 November 2020. Retrieved 25 May 2019.
Miller, John (30 October 2019). "Novartis' Zolgensma study halted by FDA amid safety questions". Reuters. Archived from the original on 30 October 2019. Retrieved 30 October 2019.
Erman M (24 September 2019). "Novartis blames former AveXis executives for Zolgensma data manipulation". Reuters. Archived from the original on 26 September 2019. Retrieved 26 September 2019.
"Statement on data accuracy issues with recently approved gene therapy". U.S. Food and Drug Administration (FDA) (Press release). 19 November 2019. Archived from the original on 19 November 2019. Retrieved 1 December 2019. This article incorporates text from this source, which is in the public domain.
"Novartis says delayed telling FDA of Zolgensma concern due to 'mistake'". Reuters. 1 November 2019. Archived from the original on 11 November 2019. Retrieved 11 November 2019.
"Zolgensma°: the drug of extremes". April 2020. p. 107. Archived from the original on 29 October 2020. Retrieved 22 May 2020.
"Novartis in talks with patients upset about lottery-like gene therapy giveaway". Reuters. 20 December 2019. Archived from the original on 1 June 2021. Retrieved 29 May 2021.
Kyriakides S (19 February 2020). "Answer given by Ms Kyriakides on behalf of the European Commission". European Parliament. Archived from the original on 28 October 2020. Retrieved 21 April 2020.
"No "lottery for life" - Statement by Beneluxa Health Ministers addressing the global managed access program designed by Novartis and Avexis". Beneluxa. 30 January 2020. Archived from the original on 22 May 2020. Retrieved 21 April 2020.
"AVXS-101 (Zolgensma) to be made available globally through a controversial programme". SMA Europe. 26 December 2019. Archived from the original on 13 March 2020. Retrieved 21 April 2020.
"Dismay at lottery for $2.1m drug to treat children with muscle-wasting disease". The Guardian. 20 December 2019. Archived from the original on 21 December 2019. Retrieved 21 December 2019.
"Novartis to Offer World's Most Expensive Drug for Free Via Lottery". The Wall Street Journal. 19 December 2019. Archived from the original on 21 December 2019. Retrieved 21 December 2019.
"Onasemnogene abeparvovec (USAN/INN)". PubChem. Archived from the original on 9 September 2021. Retrieved 9 September 2021.

worldcat.org

search.worldcat.org

Iau, Jean (19 May 2023). "Toddler with rare genetic condition can be treated after $2m raised, drug registered". The Straits Times. ISSN 0585-3923. Retrieved 20 May 2023.

wsj.com

"Novartis to Offer World's Most Expensive Drug for Free Via Lottery". The Wall Street Journal. 19 December 2019. Archived from the original on 21 December 2019. Retrieved 21 December 2019.

yahoo.com

news.yahoo.com

Erman M (24 September 2019). "Novartis blames former AveXis executives for Zolgensma data manipulation". Reuters. Archived from the original on 26 September 2019. Retrieved 26 September 2019.